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Macrophages function as sentinel cells, which constantly monitor the host environment for infection or injury. Macrophages
have been shown to exhibit a spectrum of activated phenotypes, which can often be categorised under the M1/M2 paradigm. M1
macrophages secrete proinflammatory cytokines and chemokines, such as TNF-𝛼, IL-6, IL-12, CCL4, and CXCL10, and induce
phagocytosis and oxidative dependent killing mechanisms. In contrast, M2 macrophages support wound healing and resolution
of inflammation. In the past decade, interest has grown in understanding the mechanisms involved in regulating macrophage
activation. In particular, epigenetic control ofM1 orM2 activation states has been shown to rely onposttranslationalmodifications of
histone proteins adjacent to inflammatory-related genes. Changes inmethylation and acetylation of histones bymethyltransferases,
demethylases, acetyltransferases, and deacetylases can all impact how macrophage phenotypes are generated. In this review, we
summarise the latest advances in the field of epigenetic regulation of macrophage polarisation to M1 or M2 states, with particular
focus on the cytokine and chemokine profiles associated with these phenotypes.
1. Macrophages Are a Heterogeneous
Population Tightly Controlled by
Tissue-Specific Factors
Macrophages are immune cells of myeloid lineage that
originate from the embryonic yolk sac and are an integral
component of the host’s immune response. They act as sen-
tinel cells, which constantly sample their microenvironment
and their primary function is to monitor tissues for potential
threats (e.g., infection and injury). There are a range of res-
ident macrophage populations, including microglia (brain),
Kupffer cells (liver), alveolar macrophages (lungs), splenic
macrophages, osteoclasts, bone marrow macrophages, his-
tiocytes (connective tissue), intraocular macrophages (eye),
subcapsular sinusoidal macrophages (lymph nodes), and
intestinal macrophages [1, 2].
All macrophage populations monitor their tissue of
residence and respond to pathogen-associated molecular
patterns (PAMPs) and danger-associated molecular patterns
(DAMPs) by initiating the acute inflammatory cascade. After
clearance of the pathogenic factors, resident macrophages
replenish their populations by proliferation and promote the
resolution of inflammation by clearing apoptotic cells/debris
and support wound healing and tissue repair programs [1, 3].
In addition to these generic roles, macrophages demon-
strate tissue-specific functional properties [3]. For example,
resident populations in mucosal areas come into contact
with environmental pathogens and splenic macrophages
control iron metabolism together with Kupffer cells and clear
senescent erythrocytes from the circulation. In the brain,
microglia cells play a crucial role in neuronal survival [3].
To carry out their tissue-specific functions, macrophages
respond to local signals released in their niche. For instance,
it has been shown that retinoic acid in the peritoneal cavity
and TGF-𝛽, CSF-1, and IL-34 in the brain help define
peritoneal macrophages and microglia populations, respec-
tively [2, 4]. CSF-1 and RANKL induce differentiation of
osteoclasts, CSF-2 secretion by the respiratory epithelium
matures alveolar macrophages, and IL-10 prevents excessive
intestinal macrophages activation [2, 4]. Under this constant
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conditioning, the macrophage lineage is established via
expression of signature transcription factors (TFs), which
dictate their functions not only in homeostasis, but also
during an immune response.
Examples include the ability of peritoneal macrophages
to signal via eicosanoid products, microglia to undergo
oxidative metabolism, alveolar macrophages to metabolise
lipids, and red pulp splenic macrophages to respond to
interferon activation [5]. Recently, many reports have iden-
tified core genes that define macrophage populations in the
host. Tissue-specific TF regulate tissue signature genes by
binding to motifs on enhancers to control gene expression.
For example, Spic has been shown to be the signature
TF for red pulp splenic macrophage development, Gata6
is responsible for Tgfb2, Cebpb, and Rarb expression in
peritoneal macrophages, Runx3 in intestinal macrophages,
Car4 in alveolar macrophages, Clec4f in Kupffer cells, and
Mef2c in microglia [2, 4–7]. In some cases, subpopulations
of resident macrophages may express their own selective
signature genes; for instance, small peritoneal macrophages
express Ciita, which is detected at low levels in large peri-
toneal macrophages [4].
These transcriptional differences result in selective
expression of proteins by different macrophage populations,
for instance, VCAM-1 and CD31 in splenic macrophages,
CX3CR1 and Siglec-H in microglia, ICAM-2 and CD93 in
peritoneal macrophages, CCR2 in monocytes, CLEC4F in
Kupffer cells, or CD11a and EpCAM in alveolar macrophages
[2, 5, 6]. These proteins are critical in recruiting and
integrating macrophage populations into their respective
niches.
2. Macrophage Differentiation and
Immune Responses Are Regulated by
Complex Epigenetic Changes
Macrophages are constantly sampling their ever changing
environment and have therefore evolved regulatory epige-
netic programs that define their core functions and also allow
them to respond to environmental cues rapidly.
The lineage determination of macrophages is accom-
plished by the constitutive expression of the ETS-domain TF
and PU.1. PU.1 can bind to its motifs on DNA and facilitate
stable opening of chromatin and recruitment of additional
TF (Figures 1(a) and 1(b)). It is found at macrophage
gene enhancers and promoters and contributes to enhancer
organisation [8–10]. In vitro ectopic expression of PU.1 in
fibroblast cell lines has been shown to induce the expression
of macrophage-specific genes, such as Cd68, Emr1, and
Lyz2, illustrating its significance for the establishment of the
macrophage lineage [11].
However, recent evidence has shown that PU.1 does not
establish the macrophage lineage on its own (Figure 1(b)). In
fact, PU.1 binding motifs on promoters are in close proximity
to other macrophage TF, such as AP-1, C/EBP𝛼, C/EBP𝛽, and
RUNX. Evidence from Heinz et al. suggests that cross-talk
between PU.1 and C/EBP𝛽 supports the organisation of the
macrophage enhancer landscape [8].
The basic unit of DNA organisation in cells, the nucleo-
some, consists of 147 base pairs of DNA wrapped around a
dimer of tetramers of the core histone proteins, H2A, H2B,
H3, and H4. The nucleosomes pack the DNA efficiently in
the nucleus, but at the same time they obstruct DNA from
being transcribed. In order for transcription to occur, the
core histones undergomodifications and unravel in a process
called nucleosome remodelling. Key histone modifications
that regulate gene expression include H3 andH4methylation
and acetylation [12].
During macrophage differentiation, lineage-specific
enhancers and promoters are marked epigenetically with
histone modifications [10]. Enzymes transfer methyl groups
to histone tails resulting in positive or negative regulation of
adjacent gene expression. The chemical reaction is targeted
to lysine (K) or arginine (R) residues on H3 and H4 and the
enzymes show high selectivity for their targets [13, 14]. Gene
promoters are labelled with H3K4me3, whilst enhancers
are marked with H3K4me1 (Figure 1(b)). Promoters are
invariably labelled with H3K4me3, regardless of whether
the genes are expressed or not. They may acquire additional
H3K9/14ac marks as a signature of transcription initiation
andH3K36me3 andH3K79me2 as signatures of transcription
elongation [15].
Regulation of gene expression in macrophages has been
reported to occur mainly at the level of enhancers. Active
enhancers present deposition of H3K27ac [16] and therefore
feature as H3K4me1hiH3K27achi andH3K4me3hiH3K27achi,
respectively [17]. In contrast, repressive marks on enhancers,
such as H3K27me3, indicate a poised status of activation,
meaning that particular enhancer has the potential to be
activated [17].
The combination of cell-specific TF and chromatin mod-
ifications shapes the epigenetic landscape of macrophages,
thereby defining the spectrum of responses that these cells
are capable of carrying out [17]. Each cell type possesses
a unique enhancer landscape that allows them to carry
out cell-specific functions [18]. To further illustrate the
notion that cell functions are dependent on preestablished
epigenetic patterns, Creyghton et al. showed that nuclear
reprogramming of fibroblasts into fibroblast-derived induced
pluripotent stem cells resets the global enhancer patterns to
embryonic stem (ES) cell configuration [16]. Reciprocally,
gains and losses of H3K27ac marks on genes expressed by
differentiated neural cells were observed in comparison with
ES cells and neural progenitors, which suggests that cell types
alter their epigenetic landscape during differentiation [16].
After the establishment of the macrophage lineage by
pioneer TF, some genes are additionally bound by second-
tier TF, also referred to as “primers” [19]. Exemplified byAtf3,
JunB, and AP-1, primer TF marks the potential of the cells
to respond to environmental stimuli, and it is believed that
they attract inflammation-related TF upon stimulation [19].
When macrophages are primed by an environmental cue,
they need to respond rapidly and therefore acute chromatin
remodelling is required (Figure 1(c)). PU.1 in combination
with C/EBP is responsible for the induction of many LPS-
and TNF-responsive genes [8, 20]. In addition, p300 and
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Figure 1: Epigenetic regulation in macrophages in homeostasis and inflammation. (a) During lineage establishment, the master macrophage
regulator PU.1 unpacks the tight organisation of chromatin and binds to its motifs on the DNA sequence (arrows). Additional macrophage-
restricted TFs interact with PU.1 and are subsequently recruited to the loosenedDNA resulting in establishment of nucleosome-free regions at
macrophage enhancers and promoters. (b) Enhancers are epigeneticallymarked by theH3K4me1 signature, whereas promoters are H3K4me3
labelled. Genes which are not active at baseline may be poised, meaning that their enhancers are marked by H3K27me3 signatures, rendering
them ready to promote gene transcription in the presence of an appropriate stimulus. One category of such genes is the primary response
genes, which exhibit active repression at their enhancers and are transcribed at low levels. (c) In the presence of local signals, these genes
lose the suppressive H3K27me3 mark on their enhancers and promoters and are acetylated at H3K27 by the constitutively present p300 and
recruited acetyltransferases. The produced transcripts are successfully elongated and leave the nucleus for protein synthesis. This conversion
is facilitated by inflammation-related TF, which bring enhancers close to gene promoters to initiate gene transcription.
other acetyltransferases [21, 22] are recruited to H3K4me1hi
enhancers, enriched at LPS-induced genes, where they
acetylate H3 and H4 histones [11, 22]. The recruitment of
inflammation-related TF to enhancers, such as NF-kB, IRF
proteins, AP-1, and FOS, suggests that p300, together with
the constitutively active PU.1 and recruited TF, regulates gene
expression and immune responses of these myeloid cells [11].
For example, in IFN-𝛾-stimulated macrophages, STAT1 is
recruited to selected H3K4me1hi enhancers and induces the
expression of IFN-𝛾 responsive genes [18].
Gene activation kinetics upon TLR4 ligation revealed
that the induced genes fall into two groups; the primary
response genes, induced independently of new protein syn-
thesis shortly after macrophage activation, and the secondary
response genes, the expression of which is elevated many
hours after ligation [23, 24]. Although both groups of
genes have similar H3K4me3 and H3K9/14ac distribution on
their promoters under basal conditions, the former exhibits
increased RNA polymerase occupancy at their promoters
and low levels of gene transcription [9, 25, 26]. In addition,
the promoters of primary response genes are enriched for
NF-kB, AP-1/CREB, and SRF factor motifs, whereas the sec-
ondary response genes possess interferon-sensitive response
elements (ISREs) binding sites [9].
Elegant work by Ramirez-Carrozzi et al. provided an
insight into the mechanistic framework of primary and sec-
ondary response gene expression inmacrophages during LPS
activation [27]. High CpG content in promoters of early pri-
mary response genes correlates with loosened conformation
of chromatin. In contrast, genes that lack CpG island-rich
promoters require further nucleosome remodelling by the
SWI-SNF nucleosome remodeller in order to be expressed.
4 Mediators of Inflammation
Following LPS stimulation, H4K5, H4K8, and H4K12 are
acetylated by p300 and the recruited acetyltransferases GCN5
and PCAF at both primary and secondary response gene
promoters [25].
Recently, Ostuni et al. discovered another subset of
enhancers termed latent enhancers, which are neither PU.1
norH3K4me1marked under basal conditions but are induced
upon macrophage activation [28]. Latent enhancers induce
late-transcribed genes and the TF they depend on for their
expression varies according to the environmental stimulus
responsible. Interestingly, the authors showed that removal
of IFN-𝛾 and IL-4 retained the induced H3K4me1 marks
on the enhancers and preserved these elements in poised
conformation [28].
The existence of epigenetic regulation of macrophages is
not only essential for the induction of their activation and
participation in the inflammatory process, but is also required
for the inhibition of the immune response and avoidance of
excessive inflammation and tissue damage [23]. Corepressor
complexes, such as the NCoR, SMRT, CoREST, mSin3A, and
RCoR or the CTCF factor, are recruited to gene promoters
under the basal state and need to be displaced by coactivators
of gene expression [21, 25]. Bcl-6 is a TF that controls
expression of more than one-third of all LPS-responsive
genes. It acts to antagonise NF-kB binding at enhancers and
is essential for transcriptional repression [29]. During LPS
stimulation,macrophage gene expression is tightly controlled
by inducible signal- and gene-specific regulators, which aim
to suppress gene expression at either the posttranscriptional
or the posttranslational level [21].
The remainder of this review will discuss the epigenetic
changes that occur upon activation ofmacrophages and influ-
ence polarisation to the M1 or the M2 phenotype. We focus
particularly on the role of four broad families of enzymes that
are responsible for altering the condensation of chromatin
during inflammatory conditions, resulting in gene induction
or suppression and how these enzymes interfere with the
methylation and acetylation motifs at the promoters of genes
to enhance or inhibit their transcription and dictate the
overall responses of macrophages to various environmental
stimuli.
3. Activated Macrophages Acquire
Different Polarisation States
Macrophages are activated and respond tomount an effective
immune response against potentially harmful agents, such as
PAMPs, DAMPs, or tumours. The outcome of macrophage
activation depends on the inflammatory stimulus. Histori-
cally, macrophage activation states have been summarised
under the “M1/M2 paradigm.” The M1/M2 paradigm comes
as a reflection of the TH1/TH2 paradigm of T helper cell
activation and embodies the activation status ofmacrophages
primed with IFN-𝛾, LPS, viral products, or GM-CSF (M1
macrophages or classically activated) or IL-4, IL-10, glu-
cocorticoids, or M-CSF (M2 macrophages or alternatively
activated). In many studies, M2 macrophages have been
further divided intoM2a (IL-4 induced),M2b (IgG induced),
and M2c (IL-10 and glucocorticoid induced) despite the
fact that a consensus has been reached to instead define
macrophage phenotypes based on the activator used [81].
Induction of the M1 or M2 phenotype in macrophages
is associated with a complex network of signalling inter-
mediate effectors and TF. JNK, PI3K/Akt, Notch-Jagged,
and cytokine-induced JAK/STAT pathways have all been
implicated in skewing macrophage responses to one state or
the other, leading to TF-mediated gene expression [82, 83].
Recently, microRNAs have been reported to play a pivotal
role inmacrophage polarisation andmuch attention has since
focused on their indirect contribution to immunopathologies
(reviewed in [83, 84]). Some microRNAs have been associ-
ated with M1 macrophage functions, such as miR-29b, miR-
125-a-5p, and miR-155 [85], whereas others, such as miR-21,
miR-146a, miR-155, miR-124, miR-223, and let-7c, have been
linked to the M2 macrophage anti-inflammatory properties
[86–92].
M1 activated macrophages acquire a proinflammatory
phenotype and secrete high levels of IL-12 and IL-23 and
T cell recruiting chemokines, such as CXCL9 and CXCL10,
but low levels of IL-10. M2 activated macrophages secrete
CCL17, CCL22, and CCL24 and IL-10 and express IL-1ra
on their surface [93]. M1 macrophages are poised to kill
intracellular pathogens and promote TH1 responses, whereas
M2macrophages clear parasitic infections andpromote tissue
remodelling. The two activation states can be characterised
by certain markers. For example, Nos2 and Il12 are referred
to as M1 activation markers, with Arg1, Ym1, Fizz1, and Mgl
assigned to the M2 class.
It is important to keep in mind that these polarisation
states are not stable in vivo; macrophages display a high
degree of plasticity, and activation states can often coexist
or change during disease progression upon exposure to
microenvironment nascent mediator release [81]. In support
of this, humanmacrophages primedwith a range of activation
stimuli acquired a spectrum of activated phenotypes ranging
from the classical to the alternative pathways with shared and
specific transcriptional signatures [94].
The presence of polarised macrophages has been linked
to pathologies in animal models [95]. Resembling the TH1-
TH2 paradigm, M1 macrophages have been associated with
antitumour activity [96], whereasM2 polarisedmacrophages
have been described in models of asthma and parasite
infection [97, 98]. Interestingly, adipose tissue macrophages
from lean mice have been reported to express M2 signature
genes [99], whereas high fat diet induces the recruitment
of bone marrow-derived macrophages, which express M1
markers and contribute to the pathology in the adipose tissue
[100].
It is clear that, in order to pharmacologically intervene in
diseases where macrophages play a fundamental role, there
is a need to understand the mechanisms by which these cells
acquire new phenotypes in vitro and in vivo.
4. Histone Methyltransferases (HMTs)
The domain that primarily catalyses lysine methylation is
called Suppressor of variegation-Enhancer of zeste-Trithorax
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Table 1: HMTs and DNMT involved in macrophage polarisation.
Name Family Function References
HMTs — IL-6, IL-12, TNF-𝛼, NO secretioninduction, and IL-1𝛽 secretion inhibition [30]
SETDB1 KMT1 TNF repression [31]
EHMT2 KMT1 Ifn𝛽 and ISG suppression [32]
EHMT1, EHMT2 KMT1 M2-IL-4 activation status [33]
MLL KMT2 CXCL10 induction [34]
MLL4 KMT2 CD14 membrane anchoring [35]
Ash1 KMT2 A20 production and IL-6 suppression [36]
SETD1A, ASH1,
MLL3, and MLL4 KMT2 M2-IL-4 activation status [33]
SMYD2 KMT3 Tnf, Il6, MHC-II, and CD40/80suppression [37]
SMYD3 KMT3 Alox15 induction [34]
SMYD5 KMT3 Il1𝛼, Il1𝛽, Ccl4, Tnf, and Cxcl10 repression [38]
SUV420H2 and
SETD8 KMT5 M2-IL-4 activation status [33]
EZH1 KMT6 M2-IL-4 activation status [33]
DNMT —
Cfb, Serping, Tnfsf15 induction
Arg1, Nrp1, Cxcr4, Plxnd1, Cdk18, and Fes
repression
[39]
DNMT1 — Socs1 silencing [40]
DNMT1 and
DNMT3b — Cystathionine-𝛾-lyase suppression [41]
DNMT3B — PPAR-𝛾 silencing and polarisation to M1phenotype [42]
DNMT3A and
DNMT3L — M2-IL-4 activation status [33]
(SET) and additional protein sequences define HMTs into
eight distinct subfamilies. KMT2, KMT3, and KMT7 sub-
family members leave positive marks on H3K4 and H3K36,
whereas KMT1, KMT5, KMT6, and KMT8 leave repressive
marks onH3K9,H4K20, andH3K27. KMT4 is the onlyHMTs
subfamily with no SET domain and is responsible for H3K79
methylation. SET7/9 can additionally methylate nonhistone
proteins, such as p53, NF-kB, DNA methyltransferase 1, and
others [14].
Changes in histone conformations have been extensively
reported to occur during priming of macrophages with LPS,
IL-4, and IFN-𝛾 [101]. Epigenetic effects on histones cause
the formation of DNA loops that bring together distant
chromatin sequences and regulate transcription. Innate (e.g.,
MARCO,CD200, andCD200R1), classical (e.g., H2-Eb1), and
alternative (e.g., MRC1) activation markers are some of the
genes readily affected resulting in macrophage polarisation
[101].
Macrophage polarisation is differentially regulated by
different KMT subfamilies and in some cases by different
members within one subfamily (Figure 2(a)). HMTs may
switch on the expression of genes, such as cytokine and NO
expression [30], or suppress gene expression by methylating
negative histone tails. In general terms,HMTs promote polar-
isation of macrophages towards the M2 phenotype (Table 1).
For instance, trimethylation of H3K9 by the KMT1 member
SETDB1 silences TNF transcription [31], whereas dimethy-
lation of H3K9 results in Ifn and downstream interferon-
stimulated gene (ISG) suppression in dendritic cells (DCs)
and macrophages [32].
The KMT2 members are among the most well-studied
HMTs and are associated with M1 macrophage polarisation.
The expression of MLL is enhanced in M1 polarised human
macrophages and is responsible for H3K4 trimethylation of
signature gene promoters, such as CXCL10 [34]. In con-
trast, other KMT2 members induce the transcription of
inflammation inhibitory genes, most likely to modulate or
even terminate macrophage responses. For example, Ash1
trimethylates the Tnfaip3 promoter to induce the expression
of the TLR-antagonising protein A20, which then suppresses
IL-6 secretion by peritoneal macrophages [36].
HMTs can also interfere with upstream macrophage
activation signalling. Genetic deletion of MLL4 is linked
to impaired CD14 surface expression on LPS-stimulated
macrophages. Austenaa et al. demonstrated that Pigp, an
essential component of the GPI-GlcNAc transferase, is one
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Figure 2: Histone methylation and acetylation status affect gene expression andmacrophage polarisation to theM1 or theM2 phenotype. (a)
HMTs induce the secretion of proinflammatory cytokines and chemokines in the cellmicroenvironment and stabilise the levels of CD14 on the
macrophage surface. In contrast, some HMTs suppress the expression of MHC-II and costimulatory molecules andmodulate the secretion of
proinflammatorymediators.These enzymes contribute significantly to theM2 state, inducing the expression ofM2 signature markers and the
secretion of anti-inflammatory cytokines. (b) Although histone acetylation by HATs is generically associated with gene expression initiation,
HDACs can skew the phenotype ofmacrophages equally to theM1 or theM2 phenotype. Depending on theHDACs subfamily, these enzymes
have been shown to affect proinflammatory/proresolution cytokine secretion, MHC-II and costimulatory molecule expression, secretion of
ROS and NO, and control of polarisation-determining TF, arachidonic acid (AA), and 12-hydroxyeicosatetraenoic acid (12-HETE).
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Table 2: DMTs involved in macrophage polarisation.
Name Family Function References
AOF1 KDM1 Mdc, Il12b, and Ip10 induction [43]
KDM2A KDM2 M2-IL-4 activation status [33]
JMJD2D KDM4 Il12b andMdc induction [44]
JMJD3/UTX KDM6 TNF-𝛼 secretion [45]
JMJD3 KDM6 NF-kB, CD40, and IFN signalling [46]
JMJD3 KDM6 IL-12/IL-10 increase [47]
JMJD3 KDM6 Il12b, Il23a, G-CSF, and Trem1 induction [48]
JMJD3 KDM6 Arginase-1, CD206 induction, TNF-𝛼, and IL-6 repression [49]
JMJD3 KDM6 Arg1, Retnla, and Chi3l3 induction [50]
JMJD3 KDM6 Arg1, Fizz1, Ym1,Mrc1, and Il13 induction [51]
JMJD3 KDM6 Irf4 induction [49, 51]
PHF2 KDM7 Tnf, Ccl4, Cxcl10, Il1a, Il1b, Il6, Ccl5, Irf1,Mx1, and Oas3 induction [38]
TET2 TET Il6 repression [52]
of several hypomethylated genes following MLL4 ablation in
macrophages, leading to defective CD14 GPI-anchoring on
the cell surface [35].
KMT3 enzymes have been reported to contribute to
M2 polarisation. LPS-stimulated macrophages downregu-
late SMYD2 to prevent the H3K36 dimethylation-mediated
repression of Tnf, Il6, MHC-II, and CD40/80 expression
[37]. Another member of this family, SMYD3, is overex-
pressed in M2 polarised macrophages and is responsible
for alternative activation epigenetic remodelling, such as
H3K4 trimethylation of ALOX15 [34]. Acting on a different
lysine residue, SMYD5 reversibly trimethylates H4K20 to
shut down transcription of LPS-induced genes, such as Tnf
and Cxcl10 [38].
5. DNA Methyltransferases (DNMTs)
In addition to histone methylation, DNMT enzymes carry
out DNA cytosine methylation and are divided into four
distinct families: DNMT1, DNMT2, DNMT3 (consisting of
DNMT3a, DNMT3b, andDNMT3L), and the chromomethy-
lase family, which is exclusive to plants [102].
DNA methylation occurs in intragenic, intergenic, and
CpG islands in promoter regions in mammals [103]. Methy-
lation of promoters leads to gene expression silencing, whilst
methylation of intragenic regions can induce the expression
of alternative transcripts which are tissue- and cell-specific
[103]. The presence of numerous hypomethylated regions in
intragenic and intergenic regions in macrophages is asso-
ciated with gene expression in these cells, underlining the
influence of global methylation on gene expression [104].
DNA methylation of CpG islands in gene promoters
has been shown to shift macrophages towards both M1
and M2 phenotypes by inactivating state-specific signature
genes. Methylation of CpG islands impacts negatively on the
expression of genes. For example, DNMT1 hypermethylates
SOCS1 gene promoter during LPS activation of macrophages
and prolongs the secretion of proinflammatory mediators,
such as TNF-𝛼 and IL-6 [40]. Hypermethylation of gene pro-
moters by DNMT1 and DNMT3b exacerbates the outcome
in an experimental model of atherosclerosis by repressing the
expression of cystathionine-𝛾-lyase [41].
Genome-wide methylated DNA sequencing of recruited
macrophages in ischemic muscles of hyperlipidemic and
type 2 diabetes mellitus mice revealed that Cfb, Serping, and
Tnfsf15 promoters were hypomethylated, whilst Arg1, Nrp1,
Cxcr4, Plxnd1, Cdk18, and Feswere significantly hypermethy-
lated in inflamed tissues, skewing macrophage phenotype to
the M1 lineage [39].
Similarly, DNMT3B is activated in adipose tissue macro-
phages of obese mice and silences the M2 TF PPAR-𝛾 via
methylation of CpG sites on its promoter [42]. Additional
supporting evidence comes from atherosclerosis studies,
where inhibition of DNAmethyltransferases in macrophages
results in a severe reduction in migration to plaques, adhe-
sion to the endothelium, and secretion of a broad range
of proinflammatory cytokines, chemokines, and adhesion
molecules [105]. LXR𝛼 and PPAR-𝛾 CpG sites were shown to
be hypomethylated providing a possible explanation for the
anti-inflammatory phenotype of macrophages.
6. Histone Demethylases (DMTs)
In contrast to HMTs, DMTs enzymes remove methyl groups
from histones exhibiting dynamics of chromatin remod-
eling and constant regulation of gene expression. There
are seven subfamilies of DMTs with high specificity for
their substrates (Table 2). H3K4 mono- and dimethylation
are removed by KDM1 members, but KDM2, KDM5, and
KDM6 members can also demethylate H3K4 [14]. H3K9
mono- and dimethylation are reversed by KDM3 and KDM7
subfamily members, whereas KDM4 were the first proteins
identified to catalyse removal of di- and trimethylation from
histones. The negative marks on H3K36 tails are removed
by KDM2 (mono- and dimethylation) and KDM4 (di- and
trimethylation). Finally, di- and trimethylation onH3K27 are
demethylated by KDM6, whereas mono- and dimethylation
on H3K27 are removed by KDM7 [14].
DMTs modulate polarisation of macrophages to both
M1 and M2 states (Figure 2(a)). The KDM1 member AOF1
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was shown to be recruited by c-Rel to Il12b, Mdc, and Ip10
promoters in DCs and macrophages stimulated with LPS
[43]. RecruitedAOF1 demethylatesH3K9me2 and is involved
in a feed-forward circuit to attract more NF-kB molecules
and initiate the transcription of proinflammatory genes [43].
Similarly, the KDM4 family member JMJD2D was reported
to attack H3K9me3 levels around the enhancers of Il12b and
Mdc genes in DCs and macrophages upon stimulation with
LPS and release them from active repression [44].
The most widely studied demethylase in the macrophage
polarisation field is the KDM6 member, JMJD3. JMJD3 has
been reported to affect multiple cellular processes under
inflammatory conditions in macrophages, such as tran-
scription of inflammatory genes, oxidative stress, chromatin
remodelling, cell proliferation, and differentiation [106].
JMJD3 expression is rapidly upregulated in LPS-activated
microglia through existing NF-kB molecules, STAT1/STAT3
[107, 108] and together with the other KDM6 member, UTX,
it contributes to the establishment of the M1 phenotype by
tuning gene transcription early on after stimulation [109],
before removing methyl groups from H3K27me3-repressed
M1 signature genes, such as TNF [45]. JMJD3’s role was
demonstrated in an in silico study, where it was predicted to
target the CD40, chemokine, and IFN signalling pathways
[46]. Another line of evidence suggests that in human type
2 diabetes nonhealing wounds and diet-induced obese mice,
JMJD3 is responsible for the elevated IL-12/IL-10 ratio [47]
and it has also been reported to be expressed in serum
amyloid A-primed murine macrophages as part of the proin-
flammatory cytokine secretion program [48].
In contrast, other reports have shown that deficiency
of JMJD3 in microglia leads to enhanced proinflammatory
mediator secretion, such as TNF-𝛼 and IL-6, and a reduction
in theM2markers, Arginase-1, and CD206, creating a hostile
microenvironment for neurons [49]. This result suggests
that JMJD3 may also be induced by alternative activation.
Indeed, JMJD3 is expressed in IL-4-stimulated BMDM as a
direct downstream target of STAT6 [50] and promotes the
expression of Irf4 to establish a M2 phenotype [51].
Recently, a novel family of Fe2+- and 2-oxoglutarate-
dependent dioxygenases [110], named ten-eleven transloca-
tion (TET) proteins (reviewed in [111]), were found to take
part in a number of biological processes, such as embryonic
development [112] and epigenetic regulation of gene tran-
scription and cancer [113], andmediate their effects by oxidis-
ing 5-methylcytosine inDNA to 5-hydroxymethylcytosine, 5-
formylcytosine, and 5-carboxylcytosine [114, 115].
Although TET2 and TET3 are expressed in macrophages,
their levels are not increased upon LPS stimulation, implying
that they may not play a critical role in DNA demethylation
during macrophage activation [116]. However, Zhang et
al. showed that TET2 actively represses IL-6 during the
resolution phase of inflammation [52]. The authors found
that IkB𝜁 targets TET2 to the Il6 promoter to indirectly
recruit HDAC2, which deacetylates H3 and H4 histones and
suppresses transcription.
Therefore, TET enzymes warrant further investigation as
they may regulate macrophage polarisation either directly
Table 3: HATs involved in macrophage polarisation.
Target Function References
H3K9/14
TNF-𝛼, IL-6, NOS2,
MHC-II, and CIITA
induction
[53]
H3 IFNA, TNF, and IL6expression [54]
through conversion of cytosines in gene promoter DNA
sequences or indirectly via recruitment of histone modifying
enzymes.
7. Histone Acetyltransferases (HATs)
Histone acetyltransferases are enzymes that transfer acetyl
groups to core histones, which has subsequent effects on
chromatin remodelling and gene expression. They are a
diverse group of proteins with several catalytic domains that
dictate their subunit specificity and functions. HATs are
divided into two families [117]: Gcn5 N-acetyltransferases
(GNATs) and Morf, Ybf2, Sas2, and Tip60 HATs. Other
proteins, such as p300/CBP, Taf1, and nuclear receptor coac-
tivators also possess catalytic acetyltransferase activities, but
no typical HATs domains.These proteins are considered as an
orphan class of HATs [117].
HATs have been shown to be involved in initiating gene
expression in macrophages during inflammation (Table 3).
However, to date only a limited number of reports have
detailed how HATs catalyse the expression of specific M1 or
M2 associated genes. Instead, we only have a more global
understanding of histone acetylation and its role in regulating
gene expression.
Soluble/secreted factors from the parasite M. corti were
shown to downregulate Tnf, Il6, Nos2, H2-Eb1, and Ciita
expression in LPS-primed microglia. These factors sup-
pressed H3K4me3 and H3K9/14Ac in these genes and pro-
moted RNA polymerase II recruitment to the Arg1 promoter,
causing compromised immune responses of microglia in
murine neurocysticercosis [53].
HATsmay also interact with the opposing histone deacet-
ylase enzymes to enhance acetylation and eventually acti-
vation of antiviral gene promoters. For example, p300/CBP
was shown to be recruited to the inactive Ifn𝛼 promoter
upon IRF5 phosphorylation and displace the SMRT/Sin3a
repressive complexes. IRF5 is subsequently acetylated by
p300/CBP facilitating H3 histone acetylation of target genes,
including Tnf and Il6 [54].
8. Histone Deacetylases (HDACs)
The enzymes that oppose HATs functions are referred to
as HDACs. Histone deacetylation is a dynamic process and
may be the result of other posttranslational modifications.
HDACs functions may induce further epigenetic changes
and alternative gene expression (Table 4). To date there
have been eighteen identifiedmammalianHDACs, which are
classified in five groups: Class I (HDAC1, HDAC2, HDAC3,
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Table 4: HDACs involved in macrophage polarisation.
Name Class Function References
— Classes I and II
Pattern recognition receptors, activation
markers, cytokines, chemokines, secretion of
reactive oxygen species, and NO induction
[30, 55–57]
— Classes I and II MIF induction [58]
— Classes I and II Cd16 induction, Cd206, TNF-𝛼, and NOrepression [59]
— Classes I and II PU.1 induction [60, 61]
— Classes I and II Arg1 induction [62]
— Class I IL-12, TNF-𝛼 secretion, IL-10 repression,and CD40/80 induction [63]
HDAC1 Class I IFNA and IL6 repression [54]
HDAC1 Class I Cox2, Pai1 inhibition, and Edn1 induction [64]
HDAC2 Class I Ciita inhibition [65]
HDAC2 Class I M2-IL4 activation status [33]
HDAC2 Class I Il6 repression [52]
HDAC3 Class I IFN-𝛽 secretion [66]
HDAC3 Class I TGF-𝛽 suppression [67]
HDAC3 Class I IL-6, NO secretion [30]
HDAC6 Class IIb Edn1 and Il12b induction [64]
HDAC7 Class IIa Il12b, Il6, and Edn1 induction [68]
HDAC9 Class IIa PPAR-𝛾, ABCA1, and ABCG1 repression [69]
HDAC9 Class IIa M2-IL4 activation status [33]
SIRT1 Class III Tnf, Il6, Nos2, andMcp1 represion [70]
SIRT1 Class III TNF-𝛼, IL-1𝛽, IL-6, IL-12, and MCP-1inhibition [71–73]
SIRT1 Class III PGE
2
inhibition [74]
SIRT1 Class III M2-IL4 activation status [33]
SIRT2 Class III Tnf, Il6,Mcp1 repression, Il4r, and Il10induction [75]
SIRT2 Class III Tnf, Il1𝛽, Il6, Cox2, Nos2, and reactiveoxygen species inhibition [76]
SIRT2 Class III iNOS, TNF-𝛼, IL-6, CD40/80, IL-10, andreactive oxygen species inhibition [77]
SIRT6 Class III Il1𝛽 repression [72]
HDAC11 Class IV Il10 downregulation [78, 79]
HDAC11 Class IV IL-1𝛽 repression [80]
and HDAC8), Class IIa (HDAC4, HDAC5, HDAC7, and
HDAC9), Class IIb (HDAC6 and HDAC10), and Class III
(consists of the NAD+-dependent HDACs) and HDAC11,
which constitutes a class of its own [118].
HDACs effects during macrophage activation (Fig-
ure 2(b)) have primarily been studied through the use of small
molecule inhibitors [119]. For example, inhibition of histone
deacetylases with the HDACs classes I and II inhibitor Tri-
chostatinA (TSA) in differentiating bonemarrow cells arrests
cells to the phase of proliferating progenitors. [60]. Further-
more, simultaneous inhibition of HDACs classes I and II in
several macrophage populations results in reduced levels of
pattern recognition receptors, activation markers, cytokines,
and chemokines. Secretion of reactive oxygen species, NO,
and modulation of cellular processes, such as chemotaxis,
phagocytosis, apoptosis, and cellular metabolism, have also
been reported to be affected [30, 55–57]. In a study by Lugrin
et al., the authors showed that the proinflammatory medi-
ator macrophage inhibitory factor (MIF) is a downstream
target of HDACs inhibition [58]. Inhibition of HDACs may
also be beneficial in a complex inflammatory environment,
whereby the interactions of macrophage populations with
other resident cells are detrimental to the host. In this
respect, HDACs inhibition rescued oligodendrocytes during
traumatic brain injury via induction of the M2 phenotype in
resident microglia [59].
There are many plausible explanations for the HDACs
class I and II effects on macrophage activation status. Roger
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et al. reported that HDACs inhibition enhances the recruit-
ment of the repressive complexMi-2b to the promoters of M1
activation state genes, such as Il6 [55]. Another possibility is
that these effects are a result of the decline in the PU.1 levels in
macrophages treated with TSA [60, 61]. Interestingly, Serrat
et al. proposed that TSA induces an acetylation-mediated
repression on C/EBP𝛽, which binds with lower efficiency to
the Arg1 promoter in macrophages [62].
Use of a selective class I HDACs inhibitor, valproic acid
(VPA), has been shown to reduce expression ofM1-associated
genes in macrophages, including CD40, CD80, and proin-
flammatory cytokines [63], implying that themembers of this
subfamily promote M1 activation in macrophages. Indeed,
HDAC1, HDAC2, and HDAC3 were shown to act as a
network of enzymes, aiming to enhance LPS-responsiveness
in macrophages. Strikingly, this effect is mediated not only
by histone tail modulation, but also via nonhistone protein
phosphorylation and acetylation [120, 121].
Class I HDAC1 releases the IFNA promoter from bound
repressive complexes upon interaction with p300/CBP and
subsequent acetylation and transcription initiation [54].
Halili et al. expanded our understanding of this enzyme’s
actions. The authors reported that a HDAC1 inhibitor
increased the expression of Cox2 and Pai1 and reduced Edn1,
indicating that HDAC1 may have a protective role in inflam-
matory diseases [64]. HDAC2 was reported to deacetylate
and therefore modulate Ciita expression in macrophages
[65]. In atherosclerotic plaques, such an effect may prove to
be protective; CIITA promotes expression of MHC-II and
antigen presentation to T cells, a pivotal step in transition
to chronic inflammation, whilst inhibition of CIITA rescues
collagen deposition by smooth muscle cells and eliminates
plaque vulnerability.
Studies of HDAC3 demonstrate that it promotes macro-
phage responsiveness to LPS via IFN-𝛽 production [66].This
deacetylase can lead to enhanced IL-6 and NO secretion and
inhibition of TGF-𝛽 in an atherosclerosis model [30, 67],
whereas HDAC3’s proinflammatory effects in macrophages
reflect its ability to bind to PU.1 and inhibit H3K9 acetylation
in M2 signature genes [122].
Class IIa HDACs have also been shown to promote an
M1 phenotype. In particular, a HDAC7 isoform that lacks
the N-terminal 22 amino acids was reported to interact
with the newly transcribed hypoxia-inducible factor 1-alpha
and induce the expression of Il12b, Il6, and Edn1 in TLR4-
stimulated macrophages [68]. Another member, HDAC9,
is associated with disease progression in LDLR−/− mice.
Deletion of this histone modifier resulted in improved levels
of HDL and LDL due to ABCA1 and ABCG1 upregulation
and macrophage polarisation to the M2 phenotype [69]. In
a recent report, HDAC6 inhibitors were shown to induce
the expression of Edn1 and Il12b [64]. However, the authors
concluded that HDAC6 might not work alone as HDAC6−/−
BMDM showed normal LPS-induced expression of HDACs-
dependent genes.
Studies with the Class III HDACs have revealed that
members of this enzyme subfamily behave diversely. SIRT1
levels in macrophages are dampened under inflammatory
conditions, suggesting that this HDACs and the epigenetic
changes it is responsible for are not required for cell activa-
tion [71]. Indeed, studies have shown that SIRT1 deficiency
in myeloid cells results in increased tissue infiltration of
M1 macrophages and augments inflammatory responses,
mainly due to NF-kB p65, AP-1, and FAK increased acety-
lation and increased target gene expression [70, 72–74]. In
ApoE−/− mice, haploinsufficiency of SIRT1 led to augmented
macrophage oxLDL uptake and increased foam cell forma-
tion [123].
Deficiency of another member of the Sirtuin family,
SIRT2, exacerbatedDSS colitis inmice, exemplified by higher
TNF-𝛼 and IL-1𝛽 levels, and impaired epithelial integrity
[75]. Subsequent reports confirmed that SIRT2 deficiency
increased the expression of proinflammatory genes, reactive
oxygen and nitrite species, and activation surface markers in
microglia and macrophage cell lines [76, 77]. Interestingly,
SIRT2 has been shown to act as an NF-kB p65 deacetylase,
placing microglia inflammatory responses under control.
Phosphorylation on serine 331 inactivates SIRT2 and allows
cells to undergo a proinflammatory cycle, which ultimately
leads to death and neurotoxicity in the CNS [77].
Sirtuins can form a complex network of enzymes acting
in concert to regulate inflammatory responses initiated by
macrophages. Strikingly, SIRT6 was shown to compensate
for the loss of SIRT1 in macrophages by controlling the IkB
promoter acetylation status and subsequent Il1𝛽 expression
[72].
The functions of the only HDACs Class IV member
are only now being unravelled. A couple of reports found
that HDAC11 regulates the IL-12/IL-10 ratio in antigen
presenting cells [78, 79]. HDAC11 was found to bind to
the proximal site of the IL-10 promoter and modulate the
recruitment of PU.1, Sp1, and STAT3 at late stages of LPS
activation. Given the pivotal role of IL-12 and IL-10 in T
cell activation and tolerance, this enzyme holds a lot of
promise in therapeutic intervention, where manipulation of
the adaptive immune response is of critical importance [79].
Another role attributed to HDAC11 was IL-1𝛽 suppression in
DCs and macrophages during LPS stimulation [80]. In fact,
HDACs inhibition led to upregulation of IL-1𝛽 cleavage and
maturation in a caspase 8-dependent manner, demonstrating
that HDACs inhibition may prove to be more challenging
than originally thought.
9. Concluding Remarks
Research in the field of epigenetic regulation of macrophages
during inflammation has flourished in the last decade. We
now know that methylation and acetylation sites on core
histones adjacent to inflammation-related genes are heavily
affected by epigenetic enzymes, which contribute to the
establishment andmaintenance of M1 orM2 phenotypes and
therefore dictate themagnitude and type of immune response
mounted.
HMTs are strongly associated with M2 activation by
repressing M1 phenotype signature genes and promoting the
transcription of M2 genes. Repression may occur in the basal
Mediators of Inflammation 11
state or during inflammation. In contrast, DMTs have been
linked with the M1 phenotype as a result of demethylation
of repressive sites on histones. These findings imply that
although demethylation of core histones can bemainly linked
to derepression of genes, methylation can be associated with
both gene expression when it is positive (e.g., H3K4) or
inhibition when negative (e.g., H3K9 and H3K27). However,
the timing of histone methylation/demethylation in close
proximity to gene promoters is crucial.
Accumulation of the negative H3K9me2motif at primary
response gene promoters is sufficient to actively suppress
transcription initiation [32]. Whether HMTs are recruited
to gene promoters as a result of corepressor complexes is a
common question that has been posed in recent reports and
suggests that the level of gene regulation is complex and may
outweigh a model of random attraction of these enzymes to
gene promoters [38].
In fact, negative regulation of gene expression may
involve networks of HMTs and corepressor complexes that
work cooperatively to control the derepression of a cluster
of primary response genes. In accordance with this, a differ-
ent level of cell-specific and stimulus-induced gene repres-
sion in DCs and macrophages was shown to be achieved
by deposition of H3K9me3 at upstream broad enhancers
of inflammation-related genes [44]. This method of gene
repression seems to confer cell type-specific protection from
excessive secretion of proinflammatorymediators in the basal
state and the transcriptional constraints can be applied to
various genes simultaneously [44].
As a generic model, it seems plausible to hypothesise
that HMTs need guidance by a “molecular beacon” at the
promoter DNA sequence in order to bind andmethylate their
substrates. This can be mediated by corepressor complexes,
such as NcoR, SMRT, and mSin3A, as described earlier,
that provide the anchor sites for the HMTs adjacent to
gene promoters and enhancers. Further investigation into the
patterns of interactions between corepressor complexes and
HMTs is needed and might reveal that gene regulation in
macrophages in the basal state is not as randomas itmay seem
and might be heavily dependent on the corepressor/activator
complex balance at gene promoters.
Proinflammatory mediator expression during inflamma-
tion may be downregulated either by negative methylation
effects of recruited HMTs at gene promoters or indirectly
via positive methylation (and transcription initiation) of
M2 signature or anti-inflammatory genes [36]. Hence, the
assessment of HMTs and DMTs in macrophage polarisation
needs to take into account indirect effects of these enzymes
on genes, such as TFs that actively bind to the target gene
promoters and drive the response to the M1 or the M2
phenotype.
To conclude, the epigenetic changes that occur in macro-
phages during activation by various environmental stim-
uli have attracted much interest. The strategic location of
macrophage populations complemented by the ability to
shape their functions according to the needs of the hostmakes
the enzymes responsible for their polarisation, a potential
target for therapeutic interventions. Although there are still
many open questions regarding the mode of action and
the interactions of these enzymes, the knowledge we have
acquired over the last decade hints for more effort to under-
stand the molecular pathways involved in the regulation
of gene expression of macrophages during inflammation
and the design of therapies to tackle acute and chronic
inflammatory diseases.
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